Update
on Phytoestrogens
By Dr Henri ROZENBAUM President of French Menopause Study Association
Gynaecologist and Endocrinologist
Phytoestrogens are a group of substances derived from various vegetable species, which
are characterised by a certain estrogen activity.
Phytoestrogens are plant-derived molecules of non-steroidal structure, capable of binding
to the oestrogen receptor. Depending on their concentration, endogenous sexual steroid levels
and the target organ concerned, phytoestrogens may behave agonistically or antagonistically
toward oestrogens. On the other hand, a certain number of their properties seem to result
from non-genomic mechanisms. There are many phytoestrogens, and their concentration varies
considerably from one plant to another and from one preparation to another. Phytoestrogens
are considered as food supplements: they are also sometimes called nutrients or nutraceuticals.
The products currently most in use come from soya beans. Isoflavones are most often used. Their
main active compounds are daidzein and genistein. Several questions arise regarding these OTC
products in pharmacies.
Must phytoestrogens be considered as oestrogens?
With the exception of coumestrol, phytoestrogens are characterized by:
- A greatly reduced affinity for oestrogen receptors than E2 (Oestradiol),
- A greater affinity for the β receptor than for the α1.
Overall, they have a significantly lower biological effect than oestrogens.
Are phytoestrogens effective against hot flushes?
The reduced frequency of hot flushes in Asia:
20% in China and 25% in Japan, compared to the West: 75 % in the USA, has raised the issue of
benefits of a soy-rich diet vis-a-vis climacteric symptoms.
But a number of uncertainties persist despite numerous publications on this subject, explained
by the importance of variations in individual bioavailability and the great diversity of usable
products, in terms of quality as well as dosage. After an extensive review of the literature,
Tempfer et al.2 maintain that isoflavones are especially effective in women who
have had a recent natural menopause and suffer from moderate disorders. In contrast, the effects
are modest in cases of idiopathic premature menopause, menopause induced by cancer treatment,
prolonged HRT or if isoflavones
Are phytoestrogens effective against bone loss in postmenopausal women?
Despite several publications having arrived at a favourable conclusion on markers of bone restructuring
or on bone density, most authors do not consider phytoestrogens to have a preventive effect against
osteoporosis in postmenopausal women3.
Do phytoestrogens entail a carcinogenic risk?
Endometrium The incidence of endometrial cancer is low in
countries where consumption of isoflavones is high4. The vast majority of authors agree in recognizing
that as far as usual therapeutic doses are concerned, the use of phytoestrogen does not induce any endometrial
risk. A recent publication by Palacios3-5 et al.6 has confirmed the absence of any deleterious effects
after three years of treatment: endometrial biopsy study of the thickness of the mucous membrane shows that
its dimensions remain identical to those at the beginning of treatment.
Breast, Mammographic Density Taking phytoestrogens does not alter breast density, a phenomenon confrmed
by the recent study by Palacios et al. After 3 years of treatment, the ACR (American College of Radiology)
classification, a universally accepted criterion, remained unchanged.
Epidemiological data The incidence of breast cancer is lower in several Asian countries: Japan, China,
Korea and Indonesia, than in the West7. The study of Asians who immigrated to the U.S. is particularly
interesting: the incidence of breast cancer is lower among women who immigrated at a later age than among
those who immigrated during their youth8. It remains low among those who maintained their eating
habits9 while it increases in cases of changing dietary behaviour10. Thus the incidence of breast
cancer in Asians catches up with that of Westerners from the first generation of immigrants onwards11.
Epidemiological studies in women taking phytoestrogens Several observational, case-control or cohort studies
were conducted, again with conflicting results: some authors have observed a protective effect induced by a
soy-rich consumption, others have not. A meta-analysis12 involving 14 case-control studies and 7 cohort
studies results in an RR = 0.75 (0.59 to 0.95), representing a 25% reduction in the risk of breast cancer in
women who in the past have consumed soya beans, tofu, miso or isoflavones. Another more recent study that
analyzed 174 randomized controlled trials, observed no increased risk of breast cancer among consumers of
phytoestrogens5. It is actually a complex problem because of the diversity of phytoestrogens and the many
differences between Western and Asian food, which do not concern only food content in phytoestrogens but also
in red meat and animal fats, fish, notable Vitamin D sources, etc. On the other hand, the period in which soy
is consumed may play a significant role; originally discovered in animals, this fact has recently been observed
in human clinical practice, with several studies showing a decrease in further risk of breast cancer among
adolescents who received significant soya bean contributions
13-14. In practice however, given the current
state of our knowledge, it appears inadvisable to use phytoestrogens in cases of personal history of breast
cancer, especially if treatment with aromatase inhibitors is underway.
CONCLUSION
Phytoestrogens, at least some of them, may be useful for treating hot flushes. Though their efficiency with
respect to the prevention of bone loss is not proven, we can confirm their safety with respect to the endometrium
and breast.
BIBLIOGRAPHY
-
KUIPER G.G., CARLSSON B., GRADIEN K. ET AL. Comparison of the ligand binding specificity and transcript tissue distribution of oestrogen receptor and ß Endocrinology, 1997 ; 138 : 863-870.
-
TEMPFER CL.B., BENTZ E.K., LEODOLTER S. ET AL. Phytoestrogens in clinical practice : a review of the literature Fertil. Steril. 2007 ; 87 : 1243-9
-
ROZENBAUM Henri In La Ménopause, 1 vol., Eska édit., Paris, 2008 : pp. 315-330
-
PARKIN D.M. Cancers of the breast, endometrium and ovary : geographic correlations Eur. J. Cancer Clin. Oncol. 1989 ; 25 : 1917-25
-
TEMPFER CL. B., FROESE G., HEINZE G. ET AL. Side effects of phytoestrogens: a meta analysis of randomized trials American J. Med. 2009 ; 122 : 939-946
-
PALACIOS S., PORNEL B., VASQUEZ F. ET AL. Long-term endometrial and breast safety of a specific, standardized soy extract Climacteric 2010 ; Early Online 1-8
-
ROSE D.P., BOYAR A.P., WYNDER E.L. International comparisons of mortality rates for cancer of the breast, ovary, prostate and colon, and per capita food consumption Cancer 1986 ; 58 : 2363-71
-
ZIEGLER R.G., HOOVER R.N., PIKE M.C. ET AL. Migration patterns and breast cancer risk in Asian-American women J. Nat. Cancer Inst., 1993 ; 85 : 1819-27
-
WU A.H., ZIEGLER R.G., NOMURA A.M. ET AL. Soy intake and risk of breast cancer in Asians and Asian Americans Am. J. Clin. Nutr., 1998 ; 68 (6 Suppl) : 1437S-43S.
-
LEE H.P., GOURLEY L., DUFFY S.W., ESTEVE J., LEE J., DAY N.E. Dietary effects on breast-cancer risk in Singapore Lancet 1991 ; 337 : 1197-200
-
SHIMIZU H., ROSS R.K., BERNSTEIN L., YATANI R., HENDERSON B.E., NACK T.M. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles Country Br. J. Cancer., 1991, 63 : 963-966
-
QIN L., XU J., WANG P., HOSHI K. Soyfood intake in the prevention of breast cancer risk in women: a meta analysis of observational epidemiological studies J. Nutr. Sci Vitaminol. 2006 ; 52 : 428-36
-
SHU X.O., JIN F., DAI Q. ET AL. Soyfood intake during adolescence and subsequent risk of breast cancer among chinese women. Cancer Epidem. Biomarker Prev., 2001 ; 10 : 483-88.
-
WU A.H.., WAN P., HANKIN J., TSENG C.C., YU M.C., PIKE M.C. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans
|
| |
|